Table 4.
CD57, CD62L, CD94, CD122, and CD158a expression on peripheral blood CD56+low CCR5/CXCR3−, CD56+int CCR5/CXCR3+, and CD56+high CCR5/CXCR3+ NK-cell subsets.
| A | B | C | P values | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CD56+low CCR5/CXCR3− | CD56+int CCR5/CXCR3+ | CD56+high CCR5/CXCR3+ | A versus B | B versus C | A versus C | |||||
| CD57 | % (+) cells | 66.3 ± 15.6 | (36.7–87.4) | 15.3 ± 13.7 | (1.7–42.7) | 1.3 ± 1.4 | (0.0–4.3) | <0.001 | <0.001 | <0.001 |
| MFI | 700 ± 436 | (217–1557) | 355 ± 166 | (150–703) | 165 ± 219 | (9–574) | 0.018 | 0.015 | <0.001 | |
| CV | 114 ± 34 | (77–194) | 130 ± 35 | (80–205) | 85 ± 54 | (6–155) | n.s. | n.s. | n.s. | |
|
| ||||||||||
| CD62L | % (+) cells | 35.4 ± 20.4 | (9.6–73.5) | 77.3 ± 19.0 | (41.9–95.7) | 97.3 ± 2.4 | (92.8–100.0) | <0.001 | <0.001 | <0.001 |
| MFI | 49 ± 9 | (38–65) | 119 ± 21 | (77–147) | 139 ± 30 | (91–172) | <0.001 | 0.057 | <0.001 | |
| CV | 83 ± 11 | (72–109) | 56 ± 7 | (46–71) | 47 ± 9 | (35–69) | <0.001 | 0.010 | <0.001 | |
|
| ||||||||||
| CD94 | % (+) cells | 47.8 ± 13.7 | (34.1–74.1) | 91.4 ± 6.0 | (79.2–98.4) | 98.3 ± 1.5 | (94.5–100.0) | <0.001 | <0.001 | <0.001 |
| MFI | 71 ± 18 | (50–106) | 129 ± 34 | (77–211) | 228 ± 34 | (175–286) | <0.001 | <0.001 | <0.001 | |
| CV | 56 ± 7 | (44–69) | 56 ± 11 | (41–85) | 47 ± 8 | (31–56) | n.s. | 0.039 | 0.039 | |
|
| ||||||||||
| CD122 | % (+) cells | 100.0 ± 0.0 | (100.0-100.0) | 100.0 ± 0.0 | (100.0-100.0) | 100.0 ± 0.0 | (100.0-100.0) | n.s. | n.s. | n.s. |
| MFI | 46 ± 11 | (31–63) | 77 ± 20 | (49–107) | 117 ± 32 | (79–182) | <0.001 | 0.001 | <0.001 | |
| CV | 50 ± 12 | (35–72) | 56 ± 9 | (43–79) | 46 ± 5 | (34–54) | n.s. | <0.001 | <0.001 | |
|
| ||||||||||
| CD158a | % (+) cells | 38.9 ± 30.0 | (7.9–92.9) | 9.9 ± 9.0 | (0.7–30.0) | 4.1 ± 4.9 | (0.1–19.3) | 0.001 | 0.030 | <0.001 |
| MFI | 30 ± 8 | (18–42) | 35 ± 11 | (22–57) | 41 ± 13 | (20–68) | n.s. | n.s. | n.s. | |
| CV | 61 ± 21 | (27–98) | 63 ± 20 | (31–96) | 69 ± 29 | (35–126) | n.s. | n.s. | n.s. | |
Data were obtained using the gating and analysis strategies described in Figure 2, where representative dot plots of these three NK-cell subsets are presented.
Results are expressed as mean ± standard deviation (minimum–maximum) of the percentage of positive (+) cells within each CD56+ NK-cell population, and as the mean fluorescence intensity (MFI) and coefficient of variation (CV) of CD57, CD62L, CD94, CD122, and CD158a expression in cells that stained positively for these antigens.
n.s.: not statistically significant.